Please use this identifier to cite or link to this item:
https://doi.org/10.1111/j.1399-0039.2011.01796.x
Title: | Natural killer cell engineering for cellular therapy of cancer | Authors: | Shook, D.R. Campana, D. |
Keywords: | Cell therapy Chimeric receptors Immunotherapy Natural killer cells |
Issue Date: | Dec-2011 | Citation: | Shook, D.R., Campana, D. (2011-12). Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78 (6) : 409-415. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1399-0039.2011.01796.x | Abstract: | Natural killer (NK) cells can kill transformed cells and represent a promising tool for the treatment of cancer. Their function is governed by a balance of stimulatory and inhibitory signals triggered by surface receptors. Advances in NK cell therapy require the development of dependable methods for obtaining an adequate number of effector cells; additional activation or genetic modification may further increase their anticancer capacity. A method for NK cell expansion used in our laboratory relies on a genetically modified form of the K562 myeloid leukemia cell line, engineered to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB (CD137). Expanded NK cells can be transduced with genes encoding chimeric antigen receptors that stimulate tumor cell-specific cytotoxicity. These methods for NK cell expansion and genetic modification have been adapted to large-scale, clinical-grade, Current Good Manufacturing Practice conditions and support two active clinical trials. Summarized are current efforts for NK cell immunotherapy for cancer and future perspectives. © 2011 John Wiley & Sons A/S. | Source Title: | Tissue Antigens | URI: | http://scholarbank.nus.edu.sg/handle/10635/128979 | ISSN: | 00012815 | DOI: | 10.1111/j.1399-0039.2011.01796.x |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.